Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Taylor J. Chen"'
Autor:
David C. Marciano, Chen Wang, Teng-Kuei Hsu, Thomas Bourquard, Benu Atri, Ralf B. Nehring, Nicholas S. Abel, Elizabeth A. Bowling, Taylor J. Chen, Pamela D. Lurie, Panagiotis Katsonis, Susan M. Rosenberg, Christophe Herman, Olivier Lichtarge
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
The emergence of antibiotic resistance, even against last-line antibiotics such as colistin, is a serious public health threat. To guide treatment and drug development strategies, Marciano et al. apply evolutionary action (EA) analysis to identify dr
Externí odkaz:
https://doaj.org/article/769ce09d0d21450c9e7f82f6e09d8059
Publikováno v:
Blood Advances. 7:422-435
Novel drugs are needed to increase treatment response in children with high-risk T-cell acute lymphoblastic leukemia (T-ALL). Following up on our previous report on the activation of the MAP2K7-JNK pathway in pediatric T-ALL, here we demonstrate that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353929ab15bd6261e7817605198eccd8
https://doi.org/10.1182/bloodadvances.2022008548
https://doi.org/10.1182/bloodadvances.2022008548
Autor:
Andrew Henry Lewis, Cory Seth Bridges, David Neal Moorshead, Taylor J Chen, Wa Du, Barry Zorman, Pavel Sumazin, Monica Puppi, H Daniel Lacorazza
Publikováno v:
Stem Cells
Acute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow with 5-year overall survival of less than 10% in patients over the age of 65. Limited progress has been made in the patient outcome because of the inability to selectively er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7376b7f3221c3e99c5b6c09f5fcacf40
https://europepmc.org/articles/PMC9406610/
https://europepmc.org/articles/PMC9406610/
Publikováno v:
Blood. 138:3405-3405
The remission rates of T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy in children, have improved through the years. Despite this advance, 10-20% of the patients do not respond to current therapy, and relapse leukemia is the l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129fb5d57ecc3a6a8bdbac05aa9cb736
https://doi.org/10.1182/blood-2021-151558
https://doi.org/10.1182/blood-2021-151558
Publikováno v:
Experimental Hematology. 53:16-25
Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in pediatric patients. Despite advances in the treatment of this disease, many children with T-cell ALL (T-ALL) die from disease relapse due to low responses to standard c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b17f78e93ef245e4228c4baa4fcc2c
https://doi.org/10.1016/j.exphem.2017.04.009
https://doi.org/10.1016/j.exphem.2017.04.009
Autor:
Kathleen M. Haines, Alexandria P. Cogdill, Decheng Song, Laura A. Johnson, John Scholler, Carl H. June, Regina M. Young, Boris Engels, Avery D. Posey, Michael Feldman, Taylor J. Chen, Catharina Steentoft, David M. Kranz, Thomas Daugbjerg Madsen, Robert D. Schwab, Ulla Mandel, Hans Schreiber, Henrik Clausen, Karin Schreiber, Brian Keith, Alina C. Boesteanu, Jennifer D. Stone
Publikováno v:
Immunity. 44:1444-1454
Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust responses against lineage restricted, non-essential targets in hematologic cancers. However, in solid tumors, the full potential of CAR T cell therapy is lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56500d42ca9c89d56ea1fe454f2a5cb3
https://doi.org/10.1016/j.immuni.2016.05.014
https://doi.org/10.1016/j.immuni.2016.05.014
Autor:
Toni-Ann Mistretta, Michael R. Green, Leyuan Ma, Andrew Lewis, H. Daniel Lacorazza, Koramit Suppipat, Ye Shen, Paul Pang, Julie A. Tomolonis, Taylor J Chen, Monica Puppi, Chun Shik Park, Cory Seth Bridges, Rachel E. Rau
Publikováno v:
Blood. 134(22)
Leukemia stem cells are a rare population with a primitive progenitor phenotype that can initiate, sustain, and recapitulate leukemia through a poorly understood mechanism of self-renewal. Here, we report that Kruppel-like factor 4 (KLF4) promotes di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6a1c3212e32e50c7f2f7c496617544a
https://pubmed.ncbi.nlm.nih.gov/31778543
https://pubmed.ncbi.nlm.nih.gov/31778543
Autor:
Taylor J Chen, Ye Shen, Karen R. Rabin, H. Daniel Lacorazza, Chun Shik Park, Cory Seth Bridges, Jacob J. Junco
Publikováno v:
Blood. 134:3889-3889
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and relapsed ALL is a leading cause of cancer-related death in children. While advances in frontline therapy have led to an 85% cure rate, relapsed ALL patients face a dismal prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0c07837e0a156697e911d132fe56979
https://doi.org/10.1182/blood-2019-129127
https://doi.org/10.1182/blood-2019-129127
Autor:
Maci S. Terrell, Rachel E. Rau, Taylor J Chen, Margaret A. Goodell, Karen R. Rabin, Chun Shik Park, H. Daniel Lacorazza, Matthew Miller, Vincent U. Gant, Jacob J. Junco
Publikováno v:
Blood. 134:3792-3792
Introduction: RAS-activating mutations are common in both childhood B- and T-acute lymphoblastic leukemia (ALL). Prior studies of B- and T-ALL have shown that RAS mutations become enriched during treatment in minimum residual disease-positive cases,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fd6e291ebfead43672f7f1c13b89225
https://doi.org/10.1182/blood-2019-126858
https://doi.org/10.1182/blood-2019-126858
Autor:
Laura A. Johnson, Carl H. June, Boris Engels, Jennifer Brogdon, Prachi R. Patel, Marcela V. Maus, John Scholler, Joseph A. Fraietta, Shannon E. McGettigan, Reshma Singh, John T. Seykora, Andreas Loew, Gabriela Plesa, Pramod Thekkat, Arben Nace, Akemi Kosaka, Alexandria P. Cogdill, Avery D. Posey, Tucker Ezell, Takayuki Ohkuri, Taylor J. Chen, Hideho Okada, Neeraja Idamakanti, Alina C. Boesteanu
Publikováno v:
Journal for ImmunoTherapy of Cancer. 2(Suppl 3):O1
Meeting abstracts Chimeric antigen receptors are synthetic molecules designed to re-direct T cells to specific surface antigens; CAR-modified T cells can mediate long-term durable remissions in B cell malignancies, but expanding this platform to soli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2da467db6052120af227a040c210ec9